Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Luber

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Medgenmed : Medscape General Medicine|December 22, 2005
Genetic barriers to resistance and impact on clinical responseAndrew D Luber
Expert Review of Anti-Infective Therapy|October 7, 2005
Treatment strategies for highly treatment-experienced HIV-infected patientsAndrew D Luber
Journal of the International AIDS Society|October 15, 2009
Genetic barriers to resistance and impact on clinical responseAndrew D Luber
The AIDS Reader|December 17, 2005
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomesAndrew D Luber
Medgenmed : Medscape General Medicine|July 22, 2004
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimensPeter J Ruane, Andrew D Luber
Drugs of Today (Barcelona, Spain : 1998)|May 19, 2004
EnfuvirtideJacob P Lalezari, Andrew D Luber
The AIDS Reader|September 6, 2008
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral loadDavid V Condoluci, Maryanne Andrews, Andrew D Luber
Frontiers in Immunology|September 12, 2022
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global healthHildegund C J Ertl, Sue L Currie, Andrew D Luber
Antimicrobial Agents and Chemotherapy|November 8, 2006
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteersPeter J Ruane, Andrew D Luber, Mary Beth Wire, et al.
JCI Insight|September 3, 2024
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responsesMohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Medgenmed : Medscape General Medicine|December 22, 2005
Genetic barriers to resistance and impact on clinical responseAndrew D Luber
Expert Review of Anti-Infective Therapy|October 7, 2005
Treatment strategies for highly treatment-experienced HIV-infected patientsAndrew D Luber
Journal of the International AIDS Society|October 15, 2009
Genetic barriers to resistance and impact on clinical responseAndrew D Luber
The AIDS Reader|December 17, 2005
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomesAndrew D Luber
Medgenmed : Medscape General Medicine|July 22, 2004
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimensPeter J Ruane, Andrew D Luber
Drugs of Today (Barcelona, Spain : 1998)|May 19, 2004
EnfuvirtideJacob P Lalezari, Andrew D Luber
The AIDS Reader|September 6, 2008
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral loadDavid V Condoluci, Maryanne Andrews, Andrew D Luber
Frontiers in Immunology|September 12, 2022
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global healthHildegund C J Ertl, Sue L Currie, Andrew D Luber
Antimicrobial Agents and Chemotherapy|November 8, 2006
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteersPeter J Ruane, Andrew D Luber, Mary Beth Wire, et al.
JCI Insight|September 3, 2024
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responsesMohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, et al.
Pageof 1